

# EHA 2024 Congress

June 13–16, 2024  
Madrid, Spain



## TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

# EHA 2024: Top abstracts in lymphoma and CLL

June 13–16, 2024

## Indolent and mantle cell NHL

Abstract	Title
<b>LB3439</b> <a href="#">View</a>	Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial
<b>S231</b> <a href="#">View</a>	Glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: Updated analysis from a phase I/II study
<b>S232</b> <a href="#">View</a>	Primary analysis of the phase 2 ELM-2 study: Odronextamab in patients with relapsed/refractory follicular lymphoma
<b>S233</b> <a href="#">View</a>	Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after $\geq 3$ years of follow-up: Subgroup analysis of a pivotal phase II study
<b>S234</b> <a href="#">View</a>	Epcoritamab induces deep responses in relapsed or refractory (R/R) follicular lymphoma (FL): Safety and pooled efficacy data from EPCORE NHL 1 pivotal and cycle (C) 1 optimization (OPT) FL cohorts
<b>P1138</b> <a href="#">View</a>	Preliminary safety and efficacy of BOVEN (zanubrutinib, obinutuzumab, and venetoclax) for frontline therapy for older patients with mantle cell lymphoma
<b>P1146</b> <a href="#">View</a>	Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance therapy in FL: novel results from EPCORE NHL 2 arms 6 and 7

## Hodgkin lymphoma

Abstract	Title
<b>S225</b> <a href="#">View</a>	The randomized study GHSG HD21 shows superior tolerability and efficacy of BRECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma
<b>S226</b> <a href="#">View</a>	EORTC-1537-COBRA: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: A single-arm phase II study
<b>S244</b> <a href="#">View</a>	An abbreviated course of A+AVD followed by nivolumab consolidation for frontline therapy in patients with limited stage Hodgkin lymphoma
<b>P1084</b> <a href="#">View</a>	Long-term cause-specific mortality in a cohort of 1,435 Hodgkin lymphomas treated at the national adult public cancer program in Chile over a 30-year period
<b>P1093</b> <a href="#">View</a>	Brentuximab vedotin - ESHAP significantly increases the metabolic complete remission rate versus ESHAP in relapsed classical Hodgkin lymphoma. Final results of the BRESELIBET prospective trial
<b>P2041</b> <a href="#">View</a>	Brentuximab vedotin and bendamustine for relapsed Hodgkin lymphoma: High CMR rate and manageable toxicity

T-cell lymphoma	
Abstract	Title
<b>LB3442</b> <a href="#">View</a>	ELA026 targeting of SIRP(+) immune cells results in a high response rate and improved 2-month survival of treatment-naïve malignancy-associated hemophagocytic lymphohistiocytosis in a phase 1 study
<b>S245</b> <a href="#">View</a>	Outcomes of autologous and allogeneic stem cell transplantation for T-cell lymphoma: An updated analysis of the EBMT Lymphoma Working Party
<b>S247</b> <a href="#">View</a>	Valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Efficacy by prior lines of treatment and last treatment outcome from the VALENTINE-PTCL01 study
<b>P2106</b> <a href="#">View</a>	Chidamide with azacitidine and CHOP treatment plus auto-ASCT for patients with newly diagnosed peripheral T-cell lymphoma: Interim analysis of a prospective, single center, single-arm, phase 2 trial

Aggressive B-NHL	
Abstract	Title
<b>LB3438</b> <a href="#">View</a>	Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO)
<b>S236</b> <a href="#">View</a>	Feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large B-cell lymphoma: Final analysis of the HOVON 151
<b>S237</b> <a href="#">View</a>	Englumafusp alfa (CD19/4-1BBL) combined with glofitamab is safe and shows high efficacy in patients with R/R aggressive B-NHL: Final results of the dose-escalation part of phase1 trial BP41072
<b>S238</b> <a href="#">View</a>	Biomarker-adapted treatment in high-risk large B-cell lymphoma: Long-term follow-up of a NORDIC phase II trial
<b>S239</b> <a href="#">View</a>	First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5
<b>S241</b> <a href="#">View</a>	TRANSCAR: A real-life outcome study of relapsed/refractory transformed indolent non-Hodgkin lymphoma in the context of CAR T-cells a DESCART analysis
<b>S272</b> <a href="#">View</a>	Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM
<b>P2086</b> <a href="#">View</a>	Efficacy and safety of zanubrutinib combined with R-CHOP regimen in the treatment of newly diagnosed diffuse large b-cell lymphoma with extranodal involvement: A prospective phase II trial in China

<b>P2091</b> <a href="#">View</a>	A phase II, single-arm, open-label study to evaluate the safety and efficacy of tafasitamab combined with lenalidomide in patients with relapsed/ refractory diffuse large B-cell lymphoma
<b>P2110</b> <a href="#">View</a>	Bruton tyrosine kinase inhibitors and chidamide-combined therapy in relapsed or refractory diffuse large B-cell lymphoma

## Chronic lymphocytic leukemia (CLL)

Abstract	Title
<b>S155</b> <a href="#">View</a>	Latest results from an ongoing first-in-human phase 1a/b study of NX-5948, a selective Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies
<b>S156</b> <a href="#">View</a>	Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (SONRO) in combination with zanubrutinib (ZANU) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
<b>S157</b> <a href="#">View</a>	Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study
<b>S158</b> <a href="#">View</a>	Characteristics associated with response to lisocabtagene maraleucel (liso cel) in patients (pts) with R/R CLL/SLL: Exploratory analyses from TRANSCEND CLL 004
<b>S160</b> <a href="#">View</a>	Combination of zanubrutinib + venetoclax for treatment-naïve (TN) CLL/SLL with del(17P) and/or TP53: Preliminary results from SEQUOIA arm D
<b>S161</b> <a href="#">View</a>	Minimal residual disease-guided combination of ibrutinib plus venetoclax compared to FCR in untreated patients with CLL of intermediate risk: Interim results from the phase II FILO trial.
<b>S162</b> <a href="#">View</a>	7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
<b>S163</b> <a href="#">View</a>	Single-agent epcoritamab leads to deep responses in patients (pts) with Richter's transformation (RT): Primary results from the EPCORE CLL-1 trial
<b>S164</b> <a href="#">View</a>	Combined pirtobrutinib, venetoclax, and obinutuzumab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): A phase 2 trial
<b>P699</b> <a href="#">View</a>	6-year time to next treatment (TTNT) extrapolation curve for GLOW study: First-line ibrutinib + venetoclax (I+V) offers long treatment-free period for elderly/unfit CLL patients
<b>P1841</b> <a href="#">View</a>	A phase II study of time-limited treatment with acalabrutinib plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia
<b>P1839</b> <a href="#">View</a>	Updated results of combination treatment with ibrutinib and venetoclax in patients with chronic lymphocytic leukemia and complex karyotype: 4-year follow-up



## EHA 2024

Follow us on X to keep up to date  
with the latest from the congress

**@lymphomahub**

**#EHA2024**

**View all @lymphomahub tweets from #EHA2024**



Brought to you by

